EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience

Alexander Wallace, Oliver Zhou, Minh‐Nguyet Hoang, Gabriella Porter, Claudia Padilla, Cindy Marshall

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-04 · 18 (2)

DOI: 10.1002/dad2.70377 ↗
AbstractBibliografische Angaben

Abstract

Abstract INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real‐world safety data, with a special focus on amyloid‐related imaging abnormalities (ARIA). METHODS We conducted a retrospective chart review of 146 patients treated with lecanemab according to appropriate‐use recommendations at a specialty memory center clinic. RESULTS Real‐world safety and efficacy data closely resemble published data in the Clarity‐AD trial. Thirty‐three patients (23%) discontinued treatment; all remaining patients completed at least 12 months of treatment. We observed a positive trend toward increasing ARIA edema/effusion (ARIA‐E) with increasing mean arterial pressure and a mean amyloid clearance of −90.6 at 18 months. DISCUSSION When used according to appropriate‐use recommendations, lecanemab is as safe as reported in the Clarity‐AD trial. Further investigation into real‐world data is necessary for a more complete evaluation of lecanemab's safety and efficacy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →